Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis

Who May Qualify: - Age ≥18 years - HIV-1 infection - Definite or probable tuberculosis meningitis - Standard tuberculosis meningitis treatment ≤3 days: anti TB drugs at standard doses and high-dose dexamethasone as per WHO guidelines - Signed willing to sign a consent form form by patient or relative. Who Should NOT Join This Trial: - Other concomitant neurological infection, i.e. toxoplasmosis, cryptococcosis, progressive multifocal leukoencephalopathy, bacterial meningitis, neuro-syphilis - Asymptomatic positive cryptococcal antigen in serum - HBsAg positive or anti hepatitis C virus antibodies positive - Alanine transaminase (ALT)\>5 ULN - Rifampicin-resistant TB detected by GeneXpert MTB/RIF Ultra - History of previous TB treatment in patients with GeneXpert MTB/RIF Ultra negative or unavailable - Current use of drugs contraindicated with study drugs and that cannot be safely stopped - Allergy to study drugs or any of their components - Uncontrolled opportunistic infection - Moderate to severe cardiac insufficiency (NYHA classes III / IV) - Any condition which might, in the investigator's opinion, compromise the safety of treatment and/or patient's adherence to study procedures - For women of childbearing age: 1) Pregnancy or breastfeeding; 2) Refusal to use effective contraception to be discussed with the investigator - Subjects participating in another clinical trial evaluating therapies and including an exclusion period that is still in force during the screening phase - Person under guardianship, or deprived of freedom by a judicial or administrative decision Always talk to your doctor about whether this trial is right for you.